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The identification and characterization of rare immune cell populations in humans can be facilitated by their growth
advantage in the context of specific genetic diseases. Here, we use autoimmune lymphoproliferative syndrome to identify a
population of FAS-controlled TCRαβ+ T cells. They include CD4+, CD8+, and double-negative T cells and can be defined by a
CD38+CD45RA+T-BET− expression pattern. These unconventional T cells are present in healthy individuals, are generated
before birth, are enriched in lymphoid tissue, and do not expand during acute viral infection. They are characterized by a unique
molecular signature that is unambiguously different from other known T cell differentiation subsets and independent of CD4
or CD8 expression. Functionally, FAS-controlled T cells represent highly proliferative, noncytotoxic T cells with an IL-10
cytokine bias. Mechanistically, regulation of this physiological population is mediated by FAS and CTLA4 signaling, and its
survival is enhanced by mTOR and STAT3 signals. Genetic alterations in these pathways result in expansion of FAS-controlled
T cells, which can cause significant lymphoproliferative disease.
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Inborn errors of immunity can be instructive for understanding
physiological and abnormal human immune cell differentiation
and regulation. In autoimmune lymphoproliferative syndrome
(ALPS), unusually differentiated T and B cells determine the
disease phenotype, which is characterized by chronic lym-
phadenopathy, splenomegaly, and autoimmunity. The disease is
caused by germline and/or somatic FAS (sFAS) mutations
(Fisher et al., 1995; Holzelova et al., 2004; Rieux-Laucat et al.,
1995). FAS is a transmembrane receptor expressed on all acti-
vated lymphocytes. It induces apoptotic cell death but can also
mediate nonapoptotic functions (Klebanoff et al., 2016; Le Gallo
et al., 2017; Peter et al., 2007).
Lymphoproliferation in ALPS is mainly caused by accumula-
tion of polyclonal CD3+TCRαβ+CD4−CD8− double-negative T cells
(DNTs). ALPS DNTs are predominantly CCR7−CD45RA+CD57+,
resembling terminally differentiated T cells reexpressing CD45RA
(Bleesing et al., 2002; Bristeau-Leprince et al., 2008; Rensing-Ehl
et al., 2014), but they express CD27 and CD28, similar to naive or
early differentiated T cells, and lack expression of T-BET and
KLRG1 (Rensing-Ehl et al., 2014). Moreover, they express CD45R
B220, are highly proliferative, and excessively produce IL-10
(Bleesing et al., 2001; Ohga et al., 2002). A small population of
TCRαβ+ DNTs can also be found in healthy individuals. These
DNTs are nonproliferative with a predominant CCR7−CD45RA−
effector memory phenotype and do not produce IL-10 (Fischer
et al., 2005). Physiological DNTs are also present in gut and kid-
ney and in some reports have been shown to express B220 and/or
to secrete IL-10 (Martina et al., 2016; Mohamood et al., 2008).
Increased numbers of DNTs have been observed in patients with
STAT3-activatingmutations and CTL-associated protein 4 (CTLA4)
deficiency (Besnard et al., 2018; Milner et al., 2015; Nabhani et al.,
2017). Whether these “conventional” and “disease-related” DNT
populations represent separate lineages or different states of the
same lineage has not been defined.
Models of ALPS DNT ontogeny must explain both their ac-
cumulation and their unusual differentiation. We previously
observed that small populations of CD57+CD4+ and CD8+ T cells
of ALPS patients were enriched for TCR sequences that were
also prevalent among DNTs (Rensing-Ehl et al., 2014). While
these data support that peripheral single-positive T cells (SPTs)
can transition to ALPS DNTs by loss of coreceptor expression,
they cannot easily account for the significant phenotypic dif-
ferences between conventional T cell subsets and ALPS DNTs. It
is possible that the unusual profile results from defective FAS
signaling, driving conventional T cells into the differentiation
state of ALPS DNTs. Alternatively, the unusual differentiation
program could evolve independently of FAS. In this case, T cells
with this program should be detectable in healthy individuals.
The presence of T cells with this unusual differentiation
profile has not been documented in healthy humans so far. In
this study, we combined mass cytometry and RNA sequencing
analyses to further explore the relationship of ALPS DNTs to
other T cell subsets at high resolution and identified their dis-
tinct molecular signature, which was not restricted to DNTs but
also present in subsets of CD4+ and CD8+ T cells. The detailed
characterization allowed us to identify these cells in healthy
individuals. The cellular signature of these T cells characterizes
a highly proliferative, unconventional CD38+CD45RA+T-BET−
IL-10–producing polyclonal T cell population tightly controlled
by FAS and CTLA4 and maintained by mammalian target of
rapamycin (mTOR) and STAT3 signals.
Results
DNTs in ALPS patients show a unique transcriptional profile
When initiating this study, we considered DNTs in ALPS pa-
tients a distinct, disease-specific, pathological T cell population.
We studied the transcriptional basis of their unusual dif-
ferentiation pattern and possible relation to other defined
T cell subsets by RNA sequencing analysis. We sorted DNTs,
CD8+CD57−CD28+ naive and early differentiated T cells (N+EDs)
and CD8+CD57+CD28− late differentiated effector memory T cells
(LDs) from three untreated ALPS-FAS patients (P1–P3; Table S1).
We also included CD8+ LDs of three healthy donors (HDs) to
analyze whether the FAS mutation had an impact on gene ex-
pression in this cell compartment (Fig. 1 A). The transcriptome of
ALPS DNTs clearly differed from CD8+ N+EDs and LDs of pa-
tients and HDs (Figs. 1 B and S1 A). While transcriptional profiles
of ALPS versus HD CD8+ LDs showed only 25 differentially ex-
pressed genes (DEGs; adjusted P < 0.05), 1,675 and 1,667 genes
were differentially expressed between ALPS DNTs versus CD8+
N+EDs and ALPS DNTs versus CD8+ LDs, respectively (Fig. 1, B
and C). As expected, these included molecules known to be
dysregulated, such as IL-10, FAS ligand (FASLG), KLRG1, T-BET
(TBX21), and beta-glucuronosyltransferase 1 (B3GAT1), responsi-
ble for the generation of the CD57 epitope (Fig. 1 D). Expression
of the CD45R B220 glycoform on ALPS DNTs results from high
glycosylation activity (Imai et al., 1988). Interestingly, GALNT1,
encoding a glycosylation enzyme, and seven galectin-encoding
genes were among the top up-regulated genes (Fig. 1 E). We also
found strong up-regulation of CD38, HAVCR2 (TIM3), TIGIT, and
CTLA4, typically expressed on activated, exhausted, and/or reg-
ulatory T cells (T reg cells; Fig. 1 F). We then focused on the
746 DNT-private DEGs, dysregulated compared with both CD8+
N+EDs andCD8+ LDs (Fig. 1 G).We identified 19 private up-regulated
transcription factors, including MYB and OBF1 (POU2AF1), previ-
ously found up-regulated in DNTs of Fas-deficient lpr mice (Mountz
et al., 1984; Zuo et al., 2007; Mountz and Steinberg, 1989; Figs. 1 H
and S1 B). 26 transcription factors were down-regulated (Fig. S1 C)
in ALPS DNTs. Forkhead box protein P3 (FOXP3) expression was
low (data not shown). Moreover, many of the top up- or down-
regulated genes in ALPS DNTs were not dysregulated in T reg
cells whenwe analyzed published RNA sequencing data (Schmiedel
et al., 2018; Fig. S1 D). Thus, although ALPS DNTs shared features
with N+EDs, LDs, exhausted T cells, and T reg cells, their tran-
scriptional signature unambiguously differed from these con-
ventional T cell populations and was not suggestive of any close
relationship.
ALPS patients have two phenotypically distinct
DNT populations
To further define the ALPS DNT profile, we performed mass
cytometry by time of flight (CyTOF), analyzing 34 markers on
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Figure 1. DNTs in ALPS-FAS patients show a unique transcriptional profile. (A) Gating strategy for DNTs, CD8+CD28+CD57− N+EDs, and CD8+CD28-
CD57+ LDs of three ALPS-FAS patients (P1–P3) and CD8+ LDs of three adult HDs (HD1–HD3) sorted for RNA sequencing analysis. (B) Heatmap showing all
DEGs significantly dysregulated (adjusted P < 0.05) in any comparison of ALPS DNTs versus ALPS CD8+ N+EDs, ALPS DNTs versus ALPS CD8+ LDs, ALPS CD8+
N+EDs versus ALPS CD8+ LDs, or ALPS CD8+ LDs versus HD CD8+ LDs. (C) Number of DEGs (adjusted P < 0.05) for each comparison. (D) Heatmap showing
transcripts of molecules known to be dysregulated in ALPS DNTs. (E) Heatmap of selected genes coding for lectins or enzymes involved in glycosylation.
(F) Heatmap of selected genes involved in T cell activation or differentiation. * in D–F indicates that a gene was significantly (adjusted P < 0.05) dysregulated in
at least one comparison. (G) Venn diagram showing the intersection of shared DEGs in the comparisons of ALPS DNTs versus ALPS CD8+ N+EDs and ALPS
DNTs versus ALPS CD8+ LDs (ALPS DNT “private” genes). (H) Heatmap of up-regulated transcription factors among ALPS DNT private DEGs. For all heatmaps,
the relative expression (Z-score) of genes is shown and is color coded according to the legend. Rows are scaled to have a mean value of 0 and an SD of 1.
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peripheral blood mononuclear cells (PBMCs) of seven untreated
ALPS-FAS patients (P4–P10; Table S1) and seven HDs. Interest-
ingly, t-stochastic neighbor embedding (t-SNE)–based dimen-
sionality reduction delineated two major DNT subpopulations.
One population was specifically prominent in ALPS patients
(Fig. 2 A, encircled in red) and showed a distinct profile char-
acterized by high CD38, CD45RA, CD27, and CD28 expression.
The majority of these DNTs expressed Ki67, CD57, TIM3, and
TIGIT, and a subset expressed HLA-DR, CD69, PD1, and ICOS
(Fig. 2 B). We termed this unique profile a “FAS-controlled (FC)
T cell signature” because cells with this signature are expanded
in FAS-deficient patients. Subsequent t-SNE–based visualization
restricted to TCRγδ− DNTs again separated two major pop-
ulations: FC DNT, expanded in ALPS, and a second, small DNT
population with a resting naive to effector memory phenotype
(CD45RA+/−CD28+/−CD38−Ki67−CD57−/+), which was present in
both HDs and patients with ALPS and therefore termed “con-
ventional DNTs” (cDNTs; Fig. 2 C). To further validate the two
DNT clusters, we analyzed mass cytometry data using a self-
organizing map (FlowSOM) for unsupervised clustering of all
TCRγδ− DNTs in the 14 datasets. Again, two main clusters were
generated containing subclusters with expression profiles of FC
DNTs (clusters 1 and 2) or cDNTs (clusters 3–5; Fig. 2 D). To
visualize relationships between clusters, we used Uniform
Manifold Approximation and Projection (UMAP), which also
generated two main DNT clusters (Fig. 2 E). When the five
subclusters identified by FlowSOMwere projected onto the two-
dimensional UMAP plot, they localized with the two main DNT
populations (Fig. 2 F). Because FC DNTs most homogeneously
expressed CD38 and CD45RA, we evaluated whether this com-
bination could separate FC DNTs and cDNTs. Indeed, projection
of DNT populations manually gated for these two markers
matched the two major populations in the UMAP plot (Fig. 2 G).
Of note, when projected to a UMAP plot depicting all T cells, FC
DNTs formed a distinct population, while cDNTs aligned with
CD8+ and TCRγδ+ T cells, indicating their phenotypic relation-
ship (Figs. 2 H and S2 A).
Unconventional, highly proliferative FC DNTs are present
in HDs
Unexpectedly, CyTOF analysis identified not only cDNTs but also
FC DNTs in HDs (Fig. 2, A and C; and Fig. S2 A). Subsequent flow
cytometric analyses confirmed a population of CD38+CD45RA+
cells among HD DNTs with the same CD27+CD28+Ki67+/−CD57+/−
profile as FC DNTs in ALPS patients. These T cells also highly
expressed B220 and eomesodermin (EOMES) while lacking
T-BET and KLRG1 (Fig. 3 A). Using RT-PCR, we confirmed that
the characteristic FC T cell signature genes IL10, POU2AF1, MYB,
and LGALS3 were highly up-regulated in sorted CD38+CD45RA+
FC DNTs of HDs (Fig. 3 B). Transcript levels of these genes in HD
FC DNTs were not as high as in FC DNTs of ALPS patients, but
differences were not statistically significant. Protein expression
levels of IL-10 and constitutively phosphorylated MYB were also
similar, but galectin 3 expression was lower in FC DNTs of HDs
than in ALPS patients (Fig. 3 C). To corroborate cellular identity
of FC DNTs in HDs and ALPS patients and further explore their
relationship to cDNTs, we performed additional transcriptomic
analyses. We used HD N+EDs (CD28+CD57−) CD8+ T cells as
the reference population analogous to the initial RNA se-
quencing analysis. Notably, because FC DNTs represent <1% of
TCRαβ+ T cells in HDs, we had to sort cells from buffy coats,
which may have introduced a relevant variable when com-
paring HD FC DNTs with those from fresh blood of ALPS pa-
tients. HD cDNTs differed from CD8+ N+EDs by only few DEGs
and could be clearly separated from both ALPS and HD FC
DNTs when we analyzed overall transcriptional patterns
(Fig. 3 D) as well as transcript levels of selected genes en-
coding activation/differentiation markers, lectins, and tran-
scription factors (Fig. S2, B–E). When comparing ALPS with
HD FC DNTs, we found that approximately one-third of DEGs
were similarly up-regulated, one-third of DEGs were similarly
down-regulated, and one-third of DEGs were discordantly
regulated (Fig. 3 D) relative to the reference population. The
similarly regulated DEGs included most characteristic signa-
ture genes analyzed in Fig. 1 (Fig. S2, B–E). Moreover, >80% of
the top 100 DEGs between ALPS FC DNTs and CD8+ N+EDs
were concordantly dysregulated in ALPS and HD FC DNTs
(Fig. S2 F). To better understand the transcriptional differ-
ences, we performed gene set enrichment analysis, which
showed an overall concordance of pathways predicted to be
up- or down-regulated in ALPS and FC DNTs compared with
CD8+ N+EDs. Significant differences in gene set enrichment
mainly affected pathways involved in cell cycle progression,
glucose metabolism, and mTOR signaling (Fig. 3 E). Compar-
ative analysis of protein expression of the transcription factor
HIF1A and the glucose transporter GLUT1, which are both
regulated by mTOR and promote glycolysis, confirmed higher
upregulation in ALPS FC DNTs than in HD FC DNTs (Fig. 3 F).
In summary, FC DNTs are a physiological T cell population
representing a small fraction of total TCRαβ+ DNTs in healthy
individuals that shares key features of the distinct signature
seen in FC DNTs expanded in ALPS patients.
An IL-10–biased cytokine expression profile and lack of
cytolytic molecules delineates CD38+HLA-DR+Ki67+ FC from
virus-activated T cells
FC DNTs show several key features of activated and proliferating
T cells, such as CD38, HLA-DR, and Ki67 expression. To deter-
mine the degree of phenotypic and functional overlap with
in vivo activated T cells, we compared FC DNTs of HDs with
activated CD8+ T cells from individuals with acute EBV infection.
In these subjects, CD8+ T cells were massively expanded and
showed raised CD38, HLA-DR, and Ki67 expression, similar to FC
DNTs. However, CD8+ T cells activated in the context of acute
EBV infection were predominantly CD45RA− and B220−, highly
expressed KLRG1 and T-BET, and had not up-regulated IL10,
POU2AF1, MYB, and LGALS3 (Fig. 4, A and B). For functional
analysis, we compared FC DNTs with other T cell populations in
the same HDs. FC DNTs expressed high levels of IL-10 but lacked
IFNγ, IL-2, IL-4, IL-17, and CD40 ligand, while IFNγ was the key
cytokine produced by CD8+ T cells. Moreover, FC DNTs did not
express perforin and granzyme B, indicating a lack of cytolytic
capacity (Fig. 4 C). Notably, cDNTs expressed IFNγ and cytolytic
molecules, further supporting their relationship to CD8+ T cells.
Maccari et al. Journal of Experimental Medicine 4 of 18








 user on 19 N
ovem
ber 2020
Figure 2. FC DNTs show a distinct protein expression profile differing from that of cDNTs. (A) t-SNE plots of CD3+ T cells of one ALPS-FAS patient and
one HD with manual gating of T cell subsets based on CD4, CD8, and TCRγδ expression. Major DNT populations: cDNT (blue gate) and FC DNTs (red gate).
(B) t-SNE plots of one ALPS-FAS patient showing expression levels of the indicated markers. Color codes represent expression levels of respective markers,
scaled relative to the maximum (red) and minimum (blue) expression for each individual marker across all samples. (C) t-SNE plots restricted to DNT
(CD3+TCRγδ−CD4−CD8−) shown for one ALPS-FAS patient and one HD. Red, FC DNT; blue, cDNT. Comparable results were obtained for six additional ALPS-
FAS patients and six HDs. (D) Unsupervised clustering using FlowSOM on manually gated DNTs (CD3+TCRγδ−). Dendrogram for cluster relationships and
expression levels of all included markers. (E) UMAP plots for manually gated DNTs (CD3+TCRγδ−) including all samples. (F) Distribution of the five DNT
subclusters identified by FlowSOM among the two main DNT populations in the UMAP visualization. (G) Density plot of all DNTs (CD3+TCRγδ−) showing CD38
and CD45RA expression with manual gates on FC DNTs (red) and cDNTs (blue). Manually gated populations were projected onto the UMAP plot. Red, FC DNT;
blue, cDNT. (H) Distribution of TCRγδ+, CD4+, CD8+, FC DNT, and cDNT populations among total CD3+ T cells using UMAP.
Maccari et al. Journal of Experimental Medicine 5 of 18
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Figure 3. FC DNTs are present in HDs. (A) Example flow cytometric data showing selected surface marker and transcription factor expression in FC DNTs
and cDNTs in one ALPS-FAS patient compared with one age-matched HD. Numbers in gates indicate percentages. Another 5 ALPS-FAS patients and 10 HDs
(ages 0–73 yr) were analyzed with the same panel, yielding similar results (data not shown). (B) Relative (Rel.) expression of four genes selected from the top
up-regulated ALPS DNT private DEGs identified by RNA sequencing analysis was quantified in sorted FC DNTs and cDNTs (based on CD38 and CD45RA
expression) as well as total CD4+ and CD8+ T cells from three ALPS-FAS patients and four HDs by quantitative RT-PCR. Expression was normalized to HPRT,
and mean and SD values are shown. (C) Representative histograms showing IL-10, pMYB, and galectin 3 expression in FC DNTs and cDNTs of one ALPS patient
and one HD. Summary plots showing geometric mean fluorescence intensity (GMFI) of IL-10, pMYB, and galectin 3 in FC DNTs relative to cDNTs in three or four
ALPS patients and 5 HD. Lines indicate median values. Statistical comparisons were performed using the Mann-Whitney U test. (D) Heatmap showing all DEGs
significantly dysregulated (adjusted P < 0.05) in any comparison between ALPS FC DNT, HD FC DNT, HD cDNT, and HD N+ED CD8+ T cells. Cells were sorted
from P3, P6, and P22 and from HD4, HD5, and HD6. For the FC DNT HD5 sample, RNA was pooled from four HDs to achieve sufficient RNA (HD5*). Relative
Maccari et al. Journal of Experimental Medicine 6 of 18
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Taken together, FC DNTs showed clear transcriptional, pheno-
typic, and functional differences from virus-activated T cells and
cDNTs, supporting their classification as an independent T cell
subset.
The FC T cell signature characterizes T cells across CD4/
CD8 identity
We have previously identified subsets of CD4+ or CD8+ T cells in
ALPS patients with a CD28+CD57+ phenotype resembling ALPS
DNTs (Rensing-Ehl et al., 2014; Fig. 5 A). Sorting and tran-
scriptomic analysis of these DNT-like CD4+ and CD8+ T cells
revealed high IL10 and FASLG and low TBX21 (T-BET) expression
characteristic of FC DNTs (Fig. 5 B). Moreover, in our RNA se-
quencing analysis, the CD8+CD28+CD57+ “DNT-like” population
clustered with ALPS DNTs upon principal component analysis
with a transcriptional profile separated from DNTs by only 43
DEGs (Fig. 5, C and D; and Fig. S3 A). Small CD4+ and CD8+ T cell
populations resembling FC DNTs were also detectable in our
CyTOF t-SNE analysis (Fig. 5 E). To define the FC signature in-
dependent of coreceptor expression, t-SNE was performed ex-
cluding CD4 and CD8. This allowed separation of the FC T cell
population into FC DNTs, FC CD4+ T cells, and FC CD8+ T cells
(Fig. 5 F). The presence of CD38+CD45RA+ cells among CD4+ and
CD8+ T cells with the expected B220+KLRG1−CD28+Ki67+T-BET−
phenotype and overexpression of MYB and galectin 3 was con-
firmed by flow cytometry with frequencies up to 25% of CD4+/
CD8+ T cells in ALPS patients and <1% in HDs (Fig. 5 G; Fig. S3,
B–D; and data not shown). Thus, the FC T cell signature is not
restricted to DNTs, and FC SPTs exist also in HDs.
FC T cells are present in cord blood and do not expand in the
context of acute infection
We further characterized FC T cells in healthy in-
dividuals. Frequencies of CD38+CD45RA+ FC DNTs were <1% of
CD3+TCRαβ+ T cells and ranged between 2.3% and 29% (median,
13.4%) of total TCRαβ+ DNTs (Figs. 6 A and S4 A). Importantly, FC
DNTs were already detectable in cord blood (Fig. 6 A). Absolute
numbers in peripheral blood did not increase with age (Fig. 6 B),
similarly to total CD8+ T cells and cDNTs in the same individuals
(Fig. S4 B). Cord blood FC DNTs showed the characteristic
B220+KLRG1−Ki67−/+EOMES+T-BET− features, while FAS expres-
sion was lower than in FC DNTs in peripheral blood in older
individuals (Fig. 6 C). Moreover, FC DNT frequencies were
significantly higher in secondary lymphoid organs (SLOs) than
in blood and bonemarrow (Fig. 6 D). During acute EBV infection,
percentages and numbers of FC DNTs were not increased (Fig. 6,
E and F; and Fig. S4 C). Thus, FC DNTs do not expand in the
context of acute viral infection, are present before birth, do not
accumulate with age, and are enriched in SLOs.
FC T cells in healthy individuals show increased susceptibility
to FASL-induced apoptosis, and their survival is mTOR
dependent
To address the molecular mechanisms involved in generation
and maintenance of FC T cells, we first compared their sensi-
tivity to FASL-induced apoptosis relative to other T cell pop-
ulations. FC DNTs of HDs expressed FAS (Fig. 7 A) at levels
similar to memory T cells but were more sensitive to FASL-
induced apoptosis than the other T cell subsets, including
cDNTs (Figs. 7 B and S5 A). This was not due to altered ex-
pression of the anti- and proapoptotic molecules BCL-2 and BIM
(data not shown). We then analyzed whether the mTOR de-
pendence previously described for ALPS DNTs (Völkl et al.,
2016) is a characteristic and specific feature of FC T cells. In-
deed, FC DNTs, but not cDNTs, showed increased baseline and
anti-CD3/CD28–stimulated phosphorylation of S6 (Fig. 7 C), and
this was confirmed in FC CD4+ and FC CD8+ T cells (Fig. S5 B).
Moreover, CyTOF analysis revealed that rapamycin treatment
leads to a selective decrease of FC T cells in ALPS patients (Fig. 7,
D and E). Notably, the signature of the remaining FC DNTs
was unchanged, indicating that mTOR does not drive their
unconventional differentiation. Importantly, rapamycin given
for other indications to immunologically healthy individuals
also led to selective decrease of FC DNTs (Fig. 7, F and G). Thus,
the FC T cell population is characterized by a selective hyper-
sensitivity to FASL-induced apoptosis, and its maintenance is
dependent on mTOR signaling.
CTLA4 and STAT3 contribute to the regulation of FC T cells
To further unravel the signals driving FC T cells, we followed the
observation that TCRαβ+ DNTs can also be elevated in patients
with activating STAT3 mutations or CTLA4 deficiency (Besnard
et al., 2018; Milner et al., 2015; Nabhani et al., 2017; Fig. 8 A). We
therefore analyzed T cells of such patients with DNTs >5% by
CyTOF and found that FC DNTs with the characteristic pheno-
type were expanded (Fig. 8, B and C). Their absolute numbers
were significantly raised compared with HDs in both diseases
(Fig. 8 D). FC DNTs were not expanded in four patients with
STAT3 loss-of-function mutations causing hyper-IgE syndrome
(Fig. S5 C). Notably, FC CD4+ T cells were also increased in some
patients with STAT3 gain of function (GOF) and CTLA4 defi-
ciency (Fig. 8 E).While a role for CTLA4 in controlling DNT in lpr
mice has been described (Takiguchi et al., 2000), the role of
STAT3 signals is less clear. We found that ex vivo phosphory-
lated STAT3 (pSTAT3) levels were increased in FC T cells com-
pared with cDNTs and total CD4+ or CD8+ T cells, indicating
active STAT3 signaling in vivo (Figs. 8 F and S5 D). FC DNTs
from HDs further increased STAT3 phosphorylation levels
after stimulation with STAT3-activating cytokines in vitro,
expression (Z-score) of genes is shown and is color coded according to the legend. Rows are scaled to have a mean value of 0 and an SD of 1. (E) Gene set
enrichment analysis heatmap showing the top 10 up- and down-regulated hallmark pathways in ALPS FC DNTs versus HD FC DNTs (1), ALPS FC DNTs versus
HD + N+EDs (2), or HD FC DNTs versus HD CD8+ N+EDs (3). Color code represents the −log10 P value. (F) Representative histograms showing hypoxia-
inducible factor-1α (HIF1A) and GLUT1 expression in FC DNTs compared with CD8+ T cells of one ALPS patient and one HD. Summary plots showing GMFI of FC
DNTs relative to CD8+ T cells in 10 ALPS patients and 5 HDs. Lines indicate median values. Statistical comparisons were performed using the Mann-Whitney U
test. *, P < 0.05; **, P < 0.01. ns, not significant.
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Figure 4. FC DNTs differ from virus-activated T cells. (A) Flow cytometric analyses showing the differentiation pattern of human highly activated
CD38+CD8+ effector T cells of one individual with acute EBV infection compared with HD FC DNTs. Similar results were acquired in 10 additional patients with
acute EBV infection (data not shown). (B) Transcriptional levels of four up-regulated FC genes analyzed by quantitative RT-PCR in sorted CD38+CD8+ T cells
from three donors with acute EBV infection compared with those of HD FC DNTs and HD cDNTs (n = 4). Expression levels normalized to HPRT with mean and
SD values. (C) Representative plots showing the cytokine profile and expression of perforin and granzyme B in FC DNTs, cDNTs, and CD4+ and CD8+ of one HD.
Summary plots showing percentages of IL-10+, IFNγ+, and perforin+/granzyme B+ cells in all subjects tested. Lines indicate median values. Statistical com-
parisons were performed using Ordinary one-way ANOVA with Tukey’s multiple comparisons test. **, P < 0.01; ****, P < 0.0001. ns, not significant.
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Figure 5. The FC T cell signature can be found among CD4+ and CD8+ T cells. (A) Sorting strategy for ALPS DNTs, CD4+CD28+CD57− N+EDs,
CD4+CD28−CD57+ LDs, CD4+CD28+CD57+ (ALPS DNT-like CD4+), and the respective CD8+ T cell subsets for quantitative RT-PCR and/or RNA sequencing.
(B) Expression levels of IL10, FASLG, and TBX21 (T-BET) in indicated T cell subsets of one ALPS-FAS patient (P1). Expression was normalized to HPRT. (C)
Principal component (PC) analysis (PCA) of RNA sequencing data on DNTs, CD8+ N+EDs, CD8+ LDs, and DNT-like CD8+ of three ALPS-FAS patients (P1–P3) and
CD8+ LDs of three HDs (HD1–HD3). (D) Heatmap of all genes differentially expressed (adjusted P < 0.05) in any comparison are shown for all analyzed subsets.
The relative expression (Z-score) of genes is shown and color coded according to the legend. Rows are scaled to have a mean value of 0 and an SD of 1. (E)
Example t-SNE plots showing all T cells and CD38 expression for one ALPS-FAS patient and one HD. Small populations among CD4+ and CD8+ T cells re-
sembling FC DNTs are highlighted with red gates. Similar results were seen in all seven ALPS patients and all seven HDs. (F) t-SNE visualization of all T cells
without CD4 and CD8 lineagemarkers. Example plots for one ALPS-FAS patient and one HD are shownwith CD38 expression. The FC population was manually
gated. Percentages of CD4+, CD8+, and DNTs within the FC cluster shown for all ALPS patients (n = 7) and all HDs (n = 7). Lines indicate medians. (G) Example
plots with gating and percentages of FC CD4+ of total CD4+ and FC CD8+ of total CD8+ T cells determined by flow cytometry. Similar results were obtained in
another 13 ALPS-FAS patients and 54 controls (Fig. S3 and data not shown).
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demonstrating full responsiveness (Fig. 8 G). Importantly, ad-
dition of the STAT3-activating cytokines IL-10 or IL-21 pro-
longed survival of FC DNTs, although it could not prevent the
rapid ex vivo apoptosis known to occur in the majority of FC
T cells (Figs. 8 H and S5 E). Thus, mechanistically, FC T cells are
tightly controlled by FAS and CTLA4, while their survival is
enhanced by mTOR and STAT3 signals.
Discussion
Starting from a detailed characterization of DNT cells in ALPS
patients, we describe a previously unrecognized physiological
population of highly proliferative IL-10–producing T cells. This
T cell population includes CD4+, CD8+, and DNT cells that
share a unique molecular signature separating them from
other well-defined T cell populations, including cDNTs and
virus-activated T cells. They are generated before birth, are
enriched in SLOs, do not expand in the context of acute viral
infection, and are exceptionally sensitive to FAS-mediated
apoptosis. Functionally, FC T cells represent highly prolif-
erative, noncytotoxic T cells with elevated IL-10 expression.
Mechanistically, their survival and expansion is controlled
by FAS, CTLA4, mTOR, and STAT3 signaling. Our findings
move these FC cells from the niche of aberrant coreceptor
deficient T cells expanded in a rare disease to basic T cell
immunology.
Figure 6. Impact of age, localization, and acute infections on FC T cell pool size in HDs. (A and B) Percentages of CD38+CD45RA+ FC DNTs among
CD3+TCRαβ+ T cells and absolute numbers of CD38+CD45RA+ FC DNTs/µl in peripheral blood of HDs (n = 54 and n = 47, respectively) are shown in relation to
donor age in years. Values determined in HD cord blood are depicted in red. Solid lines represent linear regression analyses. R2 and P values are shown.
(C) Example plots showing percentages and phenotypes of CD38+CD45RA+ FC DNTs in cord blood (CB; n = 3) compared with adult peripheral blood (PB; n =
10). (D) Percentages of CD38+CD45RA+ FC DNTs of CD3+TCRαβ+ T cells in HD PB (n = 54, age range the same as for A) compared with adult SLOs (n = 8) and
adult bone marrow (BM; n = 4). Lines indicate medians. Statistical comparisons were performed using the Kruskal-Wallis test. ns, not significant; ***, P < 0.001.
(E) Example plots showing percentages of CD38+CD45RA+ FC DNTs in one adult HD and one patient with acute EBV infection. (F) Summary plot depicting
percentages of CD38+CD45RA+ FC DNTs of CD3+TCRαβ+ T cells in peripheral blood of HDs (n = 54) versus patients with acute EBV infection (n = 11) in relation
to donor age.
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Figure 7. FC T cells are highly sensitive to FASL and depend on mTOR signaling. (A) Representative histogram showing FAS expression on CD4+ naive
(CD45RA+CD57−), CD4+ memory (CD45RA−CD57+), CD8+ naive (CD45RA+CD57−), and CD8+ memory T cells (CD45RA−CD57+) and FC DNTs and cDNTs (CD38
and CD45RA used for gating). Summary graph showing FAS expression (median fluorescence intensity [MFI]) on annotated T cell subsets for four adult HDs.
(B) Summary graph showing percentages of active caspase 3–positive T cells among annotated T cell populations after stimulation with increasing con-
centrations of Fc-FASL (ng/ml) in the presence or absence of the pan-caspase inhibitor Z-VAD determined in four HDs. Mean and SEM values are shown.
(C) Representative plots showing pS6 in FC DNTs compared with cDNTs ex vivo and after anti-CD3/CD28 stimulation in one ALPS patient. Similar results were
obtained in four ALPS patients. Summary plot depicting the percentages of pS6-positive cells among ex vivo FC DNTs and cDNTs of four ALPS patients. Lines
indicate medians. Statistical comparison was performed using the Mann-Whitney U test. *, P < 0.05. (D) t-SNE plots representing TCRγδ− DNTs of two ALPS
patients analyzed before and during treatment with rapamycin. (E) Summary graphs showing percentages of FC DNTs of total TCRαβ+ DNTs, FC CD4+ of total
CD4+ T cells, and FC CD8+ of total CD8+ T cells in the two ALPS patients before and during rapamycin treatment. (F) Representative plots showing FC DNTs of
one immunologically healthy individual before and during rapamycin treatment. (G) Summary plots showing percentages of FC DNTs of total TCRαβ+ DNTs and
FC DNTs or cDNT absolute numbers of the three immunologically healthy individuals before and during rapamycin treatment.
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Figure 8. FC DNTs are regulated by CTLA4 and STAT3. (A) Percentages of total TCRαβ+ DNTs in whole blood of HDs and indicated disease groups (ALPS,
n = 99; STAT3 GOF, n = 22; CTLA4 deficiency [Def.], n = 15). Values of patients included in the CyTOF analysis are highlighted with red symbols (ALPS, n = 7;
STAT3 GOF, n = 3; CTLA4 Def., n = 2). Columns indicate median values. Statistical comparisons were performed using the Kruskal-Wallis test. *, P < 0.05; ***,
P < 0.001; ****, P < 0.0001. (B) Example t-SNE plots of all DNT (CD3+TCRγδ−) showing FC DNTs (red gate) and cDNTs (blue gate) and corresponding CD38
expression for indicated patient groups. (C) Percentages of FC DNTs among total DNTs as determined by CyTOF for the indicated patient groups. Columns
indicate mean values. (D) Absolute numbers of FC DNTs according to CD38/CD45RA expression in whole blood are depicted for indicated patient groups
(ALPS, n = 10; STAT3 GOF, n = 7; CTLA4 Def., n = 8). Columns indicate median values. Statistical comparisons were performed using the Kruskal-Wallis test. **,
P < 0.01; ****, P < 0.0001. (E) Example plots showing percentages of CD38+CD45RA+ FC T cells among total TCRαβ+ DNTs and CD4+ and CD8+ T cells by flow
cytometry in indicated disease groups. Similar results were obtained in 10 HDs, 3 patients with STAT3 GOF, and 3 patients with CTLA4 Def. (F) Representative
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A first important finding of our study is the discrimination of
two major DNT subsets, which we initially observed in ALPS
patients and subsequently also detected in healthy individuals
and in other patients with primary immunodeficiencies. This
finding resolves the previously observed phenotypic differences
between bulk TCRαβ+ DNTs of HDs and of patients with ALPS or
other primary immunodeficiencies (Bleesing et al., 2002;
Rensing-Ehl et al., 2014; and unpublished data): These differ-
ences reflect variable proportions of the two DNT subsets rather
than different phenotypes of the same DNT population or dif-
ferent disease-specific DNT subsets. Notably, for diagnostic
purposes, the two DNT populations can be distinguished by only
two markers, CD38 and CD45RA. ALPS-FAS is unlikely if the
proportion of CD38+CD45RA+ cells among DNTs is <25%. How-
ever, higher percentages are not specific for ALPS-FAS and can
also occur, for example, in patients with activating STAT3 mu-
tations or CTLA4 deficiency.
FC DNTs clustered separately from other T cell populations
independent of inclusion or exclusion of CD4/CD8 in the t-SNE
analysis, indicating their phenotypic difference from other T cell
populations. In contrast, the more heterogeneous cDNTs were
distributed among CD8+ T cells and TCRγδ+ cells and had a
similar RNA expression pattern suggesting a possible CD8+ lin-
eage relationship. In support of these data, cDNTs expressed
IFNγ and cytolytic molecules similar to CD8+ T cells. Furthermore,
three subclusters could be generated for cDNTs that could be
alignedwith differentiation patterns also described for conventional
CD8+ T cells: naive (cluster 4: CD45RA+CD38−CD28+CD57−), effector
memory (cluster 5: CD45RA−CD38−CD28intermediateCD57intermediate)
and terminally differentiated T cells reexpressing CD45RA (cluster
3: CD45RA+CD38lowCD28−CD57+; Appay et al., 2008). In contrast,
the two subclusters generated for FC DNTs shared all unconven-
tional features, including combined expression of CD45RA+CD38+.
The highest variability was seen in CD57 expression, which
reflects the degree of glycosylation and/or number of cell
divisions (Brenchley et al., 2003) and thus a more or less ad-
vanced differentiation state of the same population (Fig. 2 D).
Overall, discrimination between FC DNTs and cDNTs was based
not only on transcriptome and phenotype but also on tran-
scription factor and effector molecule expression, STAT3 and
mTOR signaling, and susceptibility to rapamycin.
The next unexpected finding was that FC DNTs are present in
healthy individuals. The concept of signature identity between
the prominent FC DNTs in ALPS patients and the small frac-
tion of CD38+CD45RA+ DNTs in healthy individuals was ini-
tially based on CyTOF and flow cytometric analysis revealing
the unconventional CD38+CD45RA+B220+KLRG1−CD127− dif-
ferentiation pattern and unique transcription factor profile
(MYB+OBF1+EOMES+T-BET). However, the transcriptional dif-
ferences upon subsequent high-resolution RNA sequencing
analysis were greater than expected and raised the question
whether FC DNTs in patients with ALPS and HDs are different
cell types or whether they represent variable differentiation
states of the same cell type. We postulate cellular identity based
on the following arguments: The shared dysregulated genes
include the vast majority of genes characteristic of ALPS FC
DNTs relative to other resting or in vivo activated T cells (acute
EBV infection). Dysregulation of these genes not only is based
on transcriptome data but also has largely been validated by
quantitative PCR and/or protein expression. They include unique
differentiation markers or unconventional marker combina-
tions that have not been described in any other known T cell
differentiation subset, a unique transcription factor profile,
constitutive mTOR and STAT3 activation, proliferative behav-
ior, characteristic effector molecule expression, and high sen-
sitivity to FAS-mediated apoptosis induction. These features
likely represent the “core signature” of FC T cells. Differences
between the two populations mainly affected genes involved in
cell cycle progression, glycolysis, and mTOR signaling. They
likely reflect prolonged survival, activation, and uncontrolled
proliferation of ALPS FC DNTs compared with their HD coun-
terparts in the context of defective FAS signaling. Thus, although
FC T cell fate determination occurs in a FAS-proficient envi-
ronment with acquisition of key features already before birth,
the differences between ALPS and HD FC DNTs indicate that lack
of FAS-mediated apoptosis (and possibly also of FAS-mediated
nonapoptotic signaling) prolong hyperactivation and uncon-
trolled proliferation, favoring further changes in transcrip-
tion and protein expression.
Another key finding of our study is that the FC T cell signa-
ture is shared by subsets of CD4+ and CD8+ T cells in ALPS pa-
tients and HDs and therefore represents a cellularly and
molecularly defined differentiation state that is not linked to
CD4 or CD8 identity. High-resolution analysis revealed that the
signature of FC SPTs and FC DNTs in ALPS patients is virtually
identical. This may indicate that transcriptional downregulation
of CD4/CD8 coreceptors is not an early event in FC T cell on-
togeny, but a late differentiation step for some if not all FC
T cells. It has been controversially debated for decades of murine
and human research whether ALPS/lpr DNTs differentiate from
chronically activated conventional T cells when sufficient FAS
signals are lacking or whether they represent a rare physiolog-
ical T cell subset that is efficiently eliminated in FAS-competent
individuals and therefore has so far escaped detection (Bristeau-
Leprince et al., 2008; Fortner et al., 2011; Pestano et al., 1999;
Russell et al., 1993; Trimble et al., 2002; Mohamood et al., 2008;
Hughes et al., 2008). Our data prove that these proliferating
CD38+CD45RA+IL10+ FC T cells represent a physiological subset
of the human T cell compartment that evolves independent of
the presence or absence of intact FAS signaling. Moreover, the
histograms showing pSTAT3 in FC DNTs and cDNTs of one ALPS patient and one HD. Comparable results were obtained for six additional ALPS patients.
(G) Summary plots showing baseline geometric mean fluorescence intensity (gMFI) levels for pSTAT3 in FC DNTs and cDNTs (left) and fold changes of pSTAT3
after stimulation with IL-21 (right) in cells of seven HDs. Statistical comparisons were performed using the Wilcoxon test. ns, not significant; *, P < 0.05.
(H) Flow cytometry plots showing percentages of viable (annexin V−) FC DNTs of one ALPS patient at day 0 and after 24 h of stimulation with medium alone or
with medium supplemented with IL-10 or IL-21. Data were generated in five to nine ALPS patients with similar results (Fig. S5 E). SSC, side scatter.
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clear transcriptional difference to late differentiated CD57+CD8+
T cells as well as their separation upon clustering analysis ren-
ders the concept of transition from terminally differentiated
conventional T cells highly unlikely.
FC T cells were already detectable in cord blood of HDs, and
numbers slightly declined with age. Clinically, these findings are
consistent with onset of lymphoproliferation in utero in patients
with biallelic FAS mutations and reduction of lymphoprolifera-
tion in ALPS patients beyond adolescence (Price et al., 2014).
They imply that FC T cells are generated and achieve their dis-
tinct transcriptional program prenatally, are maintained under
homeostatic control by FAS, and decrease in parallel with age-
dependent thymic involution. FC DNTs do not expand in the
context of viral infection, indicating that they are poorly reactive
to conventional stimulation or do not include antiviral TCR
specificities.
The signature of FC T cells comprised expression of a unique
combination of transcription factors. MYB, DNA-binding pro-
tein inhibitor ID3, and EOMES, all elevated in FC T cells, pro-
mote stemness and genome stability and further support high
proliferative potential (Gautam et al., 2019; Ji et al., 2011;
Intlekofer et al., 2005; Kaech and Cui, 2012). Of note, MYB also
restrains effector differentiation via repression of the tran-
scription factor ZEB2, which was indeed significantly down-
regulated (log2 fold change, −4.4) in ALPS DNTs compared
with LD CD8+ T cells and EBV-activated CD8+ T cells (not
shown). FC T cells also lack T-BET, another driver of effector
differentiation. The absence of T-BET in FC T cells was unex-
pected because T-BET upregulation has been linked to T cell
activation and mTOR signaling (Intlekofer et al., 2005; Joshi
et al., 2007; Rao et al., 2010). Indeed, all in vivo activated CD8+
T cell subsets, both effector and exhausted, highly up-regulated
T-BET and its downstream target KLRG1 (Fig. 4 and data not
shown). Interestingly, there was no heterogeneity among FC
T cells regarding their EOMEShigh/T-BET− pattern, indicating
early imprinting of this profile. Increased S6 phosphorylation
and mTOR dependence, previously demonstrated for total ALPS
DNTs (Teachey et al., 2009; Völkl et al., 2016), are selective
features of FC T cells also in HDs. Consistently, cDNTs are not
affected by rapamycin treatment of ALPS patients. Moreover, FC
DNTs were also specifically reduced in otherwise healthy in-
dividuals treated with rapamycin for vascular malformations.
Interestingly, in both ALPS patients and immunologically
healthy subjects, the signature of the FC DNTs detectable under
rapamycin was unchanged based on our CyTOF marker panel,
indicating that rapamycin eliminates mTOR-dependent FC
T cells but does not revert key features of their unconventional
cellular program. This implies that mTOR promotes expansion
of FC T cells but not FC fate determination.
Finally, our study provides insights into the molecular regu-
lation of FC T cell homeostasis. FAS plays the key role in regulating
their pool size. It is striking that among all FAS-expressing T cells,
FC T cells are most sensitive to FAS-mediated apoptosis. This can
be seen in vitro but is even more evident in vivo, where FC T cells
constitute the great majority of accumulating cells in ALPS pa-
tients. Susceptibility to FAS-mediated apoptosis is regulated at
multiple levels, including lipid raft localization, death-inducing
signaling complex (DISC) composition, cellular FLICE (FADD-like
IL-1β–converting enzyme)-inhibitory protein (c-FLIP) levels, ex-
pression of antiapoptotic molecules, activation and cell cycle sta-
tus, metabolism, and signaling context (Buchbinder et al., 2018;
Gajate andMollinedo, 2015; Gulbins et al., 1996; Larsen et al., 2017;
Wajant, 2014). FC T cells are highly activated and proliferating,
both factors known to render T cells more susceptible to FAS-
induced apoptosis, while BCL-2 and BIM expression levels were
not different between HD FC DNTs, cDNTs, and memory CD4+/
CD8+ T cells (not shown). The decisive factors determining en-
hanced FAS apoptosis sensitivity beyond features associated with
their highly activated status remain to be defined but could in-
volve the many uniquely dysregulated signal-modulating mole-
cules. We show that STAT3 is another important regulator of FC
T cell homeostasis. Baseline STAT3 phosphorylation in FC T cells
of HDs is increased ex vivo. Moreover, IL-10 and IL-21 stimulation
can prolong survival of FC T cells in short-term in vitro cultures.
Consistently, we observed increased FC T cells in patients with
activating STAT3 mutations. Notably, decreased sensitivity to
FAS-mediated apoptosis has been reported in single patients with
STAT3-activating mutations (Milner et al., 2015; Nabhani et al.,
2017), suggesting that apart from enhancing survival, STAT3 sig-
naling may contribute to FC T cell expansion by impacting FAS
signaling. Finally, the increase of FC T cells in patients with CTLA4
deficiency indicates that CD28 also plays a role in FC T cell ex-
pansion. This is supported by the significant reduction of absolute
DNT numbers after treatment of neonatal lprmice with abatacept
(Takiguchi et al., 2000).
Why are FC T cells generated, and what is the function of
these cells? It has been proposed that Fas-regulated cells repre-
sent “useless” mis-selected CD8+ T cells that lack peripheral
inhibitory peptide MHC interactions (Pestano et al., 1999) or
potentially autoreactive T cells homeostatically proliferating in
response to limited self-peptide–MHC contacts (Fortner et al.,
2011; Trimble et al., 2002). However, it is not obvious why such
“useless” cells should be so highly proliferative and secrete co-
pious amounts of cytokines. Moreover, we found that they lack
CD25 and IL-7 receptor α chain expression and do not respond to
the homeostatic cytokines IL-7 and IL-15 in vitro (data not
shown). Alternatively, they may represent T cells with sup-
pressive function destined to populate nonlymphoid organs
(Martina et al., 2016; Mohamood et al., 2008). Proliferation and
IL-10 production are key features of FC T cells, while they do not
express IFNγ and cytolytic molecules. Unfortunately, human FC
T cells very rapidly die ex vivo, rendering their functional as-
sessment difficult. The better definition of their molecular sig-
nature and the demonstration of their presence in healthy
individuals in this study will spur interest in further exploration
of the ontogeny and biological function of this unusual T cell
population.
Conceptually, the view of FC T cells emerging from our data
shares interesting parallels with “rogue” B cells: murine studies
showed that Fas is dispensable for negative selection of con-
ventional self-reactive B cells but selectively eliminates uncon-
ventional “rogue” B cells that undergo somatic hypermutation,
survive independently of antigen, and develop into (auto)anti-
body-producing plasma cells (Butt et al., 2015). These “rogue”
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B cells represent a small, proliferating B cell population in wild-
typemice tightly controlled by Fas. By analogy, Fas does not play
a major role in the regulation of conventional virus-reactive
T cells in vivo (Ehl et al., 1996; Zimmermann et al., 1996),
while it controls a small proliferating T cell population. Hence,
FC T cells may represent “rogue” T cells, potentially sharing key
features with their B cell counterparts. A better understanding
of these unusual cells and their differentiation program is rel-
evant because their uncontrolled proliferation is associated with
lymphoproliferative disease and a high incidence of autoim-
munity, as illustrated in ALPS patients.
Materials and methods
Patients and HDs
42 patients with ALPS-FAS/sFAS, GOF STAT3mutations, CTLA4
deficiency, or loss-of-function STAT3 mutations were included.
Table S1 summarizes genetic and clinical characteristics. All
patients were not receiving immunosuppressive treatment at
the time of analysis, except for P23 (under low-dose rapamycin)
and P28 (under low-dose cyclosporine and tocilizumab). Two
ALPS patients (P7 and P11) were analyzed before and under ra-
pamycin treatment (rapamycin levels in blood 3.2 and 3.7 ng/ml,
respectively). 11 individuals (mean age, 18 [4–51] yr) with acute
primary EBV infection and 54 HDs (i.e., without personal or
family history of immunological disorders and normal blood
counts; mean age, 32 [0–73] yr) were also studied. Three im-
munologically healthy individuals who started rapamycin
treatment for vascular malformations were also included in the
study. Rapamycin levels in blood ranged from 3.8 to 9.2 ng/ml.
All participants gave informed consent. The study was con-
ducted according to the Declaration of Helsinki and approved
by ethics committees of the University of Freiburg (protocol
numbers 409/16, 282/11, 610/15, 147/15, 174/13, 121/11, 251/13)
and the University of Erlangen (protocol number 219_14 B).
Flow cytometry and cell sorting
Flow cytometry was performed with peripheral blood, buffy
coats, cord blood, and lymphoid organ samples (Table S2). An-
tibodies used are summarized in Table S3. CD38 and CD45RA
expression was measured in all HDs, and comparable expression
patterns of B220, CD57, and KLRG1 and of CD27, CD28, HLA-DR,
Ki67, EOMES, and T-BET (shown in Fig. 3 A) were confirmed in
20 and 10 HDs, respectively. For intranuclear staining, the Hu-
man Regulatory T Cell Staining Kit (eBioscience) was used. To
measure cytokine production, 4 × 106 PBMCs were stimulated
with PMA (Sigma-Aldrich; 50 ng/ml) and ionomycin (Sigma-
Aldrich; 1 µg/ml) for 4 h and then analyzed using the Cytofix/
Cytoperm Plus Kit and Golgi Plug (BD Biosciences). Similarly,
IL-10 production was determined after 5 h of PMA/ionomycin
stimulation as described elsewhere (Haug et al., 2019). S6 S240
phosphorylation was analyzed using Phosflow reagents as de-
scribed previously (Völkl et al., 2016). pSTAT3 was measured
using the PerFix Expose Kit (Beckman Coulter) and analyzed
with or without cytokine stimulation for 15 min (100 ng/ml IL-
21; Miltenyi Biotec). Data were acquired with a Gallios or Navios
flow cytometer (Beckman Coulter). Data were analyzed using
FlowJo 7.2.5 or 10.4 software (FlowJo LLC). Cell populations were
either magnetically enriched using the Double-negative T cell
Isolation Kit (Miltenyi Biotec) or sorted with the MoFlo Astrios
(Beckman Coulter) or FACS Aria Fusion (Becton Dickinson) cell
sorter.
Ex vivo apoptosis assay
3 × 106 PBMCs per well were seeded into 12-well plates and
stimulated with increasing concentrations of recombinant Fc-
FASL (Holler et al., 2003) for 2 h. Some cells were pretreated
with the pan-caspase inhibitor Z-VAD-FMK 50 µM (Sigma-
Aldrich) for 30 min before Fc-FASL treatment. Early apoptotic
cells were determined by flow cytometry after intracellular
staining of active caspase 3 (BD Biosciences).
Survival assay
2 × 105 PBMCs per well were seeded into 96-well plates and
stimulated either with medium alone or with medium plus IL-
2 (100 U/ml; R&D Systems), IL-21 (100 ng/ml; Miltenyi Biotec),
or IL-10 (100 ng/ml; R&D Systems) for 24 h. Survival was
measured by flow cytometry, and annexin V staining was per-
formed using the annexin V binding buffer (BD PharMingen).
CyTOF
Sample preparation was performed as described previously
(Fuchs et al., 2019) with antibodies listed in Table S4. A Helios
mass cytometry instrument (Fluidigm) was used for sample
acquisition. Data analysis was performed with Cytobank soft-
ware with t-SNE for data visualization (Amir et al., 2013). UMAP
version 2.1 (Becht et al., 2019) and FlowSOM (Van Gassen et al.,
2015) were used as plugins for FlowJo version 10.4. Detailed
information for figures depicting CyTOF data are provided in
Table S5 (vi-SNE) and Table S6 (UMAP).
RNA sequencing analysis
DNT and CD8+ T cell populations of ALPS-FAS patients (P1 and
P2: peripheral blood; P3: spleen) and blood of three HDs (HDs
1–3) were FACS sorted on the basis of CD28 and CD57 expression.
In a second RNA sequencing experiment, DNT and CD8+ T cell
subsets of three ALPS-FAS patients (P3: spleen; P6 and P22:
peripheral blood) and three HDs (HDs 4–6: peripheral blood
buffy coats) were sorted on the basis of CD28, CD57, CD38, and
CD45RA expression. Because RNA amounts of HD FC DNTs were
very low, we pooled RNA from four different HDs for the HD5
sample (HD5*). HD6 FC DNTs had to be excluded from the
analysis because read numbers were too low. RNA sequencing
steps included RNA isolation (Qiagen RNeasy Micro Kit), RNA
quality analysis (2100 Bioanalyzer; Agilent Technologies), cre-
ation of barcoded RNA sequencing libraries (from 100 ng total
RNA with Ovation Human RNA-Seq system; NuGEN), and de-
pletion of ribosomal RNAs (insert-dependent adaptor cleavage
method; NuGEN) as described previously (Eisenhut et al., 2016;
Müller et al., 2017). To control sources of variability, a common
set of external spike-in RNA controls (by the external RNA
controls consortium) was used (Ambion). Libraries were sub-
jected to single-end sequencing (101 bp) on a HighSeq 2500
platform (Illumina). Reads mapping to, for example, ribosomal
Maccari et al. Journal of Experimental Medicine 15 of 18








 user on 19 N
ovem
ber 2020
RNAs, transfer RNAs, small nuclear RNAs, and interspersed
repeats were first filtered out using bwa-mem version 0.7.8-
r455 (Li, 2013), keeping only unmapped reads. Subsequently,
reads were mapped against the hg19 reference genome with
STAR aligner version 2.4.0j (Dobin et al., 2013) and STAR ge-
nome directory created by supplying an Ensembl gtf annotation
file (version 2013-09) for hg19. Absolute read counts per gene
were produced using Subread’s featureCounts program version
1.4.6-p2 (Liao et al., 2014) and the Ensembl gtf annotation file.
Subsequent analyses were performed using R 3.2.1 (R Core Team,
2015). Genes with low expression (total raw counts across the 15
samples ≤5) were filtered out, and differential expression
analysis was performed with the DESeq2 package version 1.8.1
(Love et al., 2014). Significantly regulated genes were selected
based on their adjusted P value (Benjamini and Hochberg) <0.05.
Publicly available RNA sequencing data (Schmiedel et al.,
2018; https://dice-database.org/landing) from sorted human
regulatory FOXP3+ T cell subsets (naive T reg cells: CD3+CD4+
CD25hiCD127lowCD45RA+; memory T reg cells: CD3+CD4+CD25hi
CD127lowCD45RA−) were used to analyze expression of genes
found dysregulated in ALPS DNTs in human T reg cells versus T
naive (CD3+CD4+CD45RA+CCR7+).
Gene set enrichment analysis was performed using GAUGE R
package version 2.36 (Luo et al., 2009) with MSigDB gene sets
version 7.0 (Subramanian et al., 2005). An adjusted P value
<0.05 was considered significant.
Quantitative RT-PCR
RNA was isolated with the RNeasy Mini Kit (Qiagen). For cDNA
synthesis, the qScript cDNA Supermix (Quantabio) or the Pri-
meScript RT Reagent Kit (Takara Bio) was used. RT-PCR was
performed using the Mastercycler Realplex instrument (Ep-
pendorf) and FastStart Universal SYBR Green Master (ROX;
Roche). Gene expression was normalized to hypoxanthine
phosphoribosyltransferase (HPRT) and calculated with the 2−ΔCt
method.
Statistical analysis
Statistical analyses were performed with GraphPad Prism soft-
ware. t Tests (Mann-Whitney U tests), the Wilcoxon test or
ANOVA, the Kruskal-Wallis test for multiple comparisons, and
mixed-effects analysis with Tukey’s multiple comparisons test
were applied to compare T cell marker expression or frequencies.
Data-sharing statement
RNA sequencing data are available under Gene Expression Omnibus
accession no. GSE154929.
Online supplemental material
Fig. S1 shows additional transcriptional features of ALPS DNTs
and a comparison to T reg cells. Fig. S2 shows UMAP projections
of the main T cell populations in ALPS patients versus HDs and a
comparison of transcript levels in ALPS FC DNTs versus HD FC
DNTs. Fig. 3 shows transcriptional and phenotypic features of FC
CD4+ and FC CD8+ T cells as well as their percentages in ALPS
patients. Fig. S4 reports percentages and absolute numbers of
different T cell populations in HDs related to age. Fig. S5 shows
representative plots of active caspase 3 staining, pS6 in FC CD4/
CD8+ T cells, FC DNT phenotype in patients with different pri-
mary immunodeficiencies, and the impact of STAT3-activating
cytokines on STAT3 phosphorylation and survival of FC T cells.
Table S1 depicts clinical, immunological, and genetic features of
included patients. Table S2 reports the sources of SLO and bone
marrow samples. Table S3 lists flow cytometry antibodies. Table
S4 lists antibodies used for CyTOF. Table S5 and Table S6 show
CyTOF analysis information for t-SNE and UMAP visualizations,
respectively.
Acknowledgments
We are grateful to the patients and their families who made this
study possible. We thank the Center for Chronic Immunodefi-
ciency Advanced Diagnostics Unit, the Center for Chronic Im-
munodeficiency Biobank as a partner of the FREEZE Biobank,
and the Lighthouse Core Facility for excellent support. We thank
Francesca Oprandi for figure processing.
This work was funded by the Wilhelm Sander Stiftung
(1 027 087 401) and the German Federal Ministry of Education
and Research (grant BMBF 01 EO 0803 to the Center of Chronic
Immunodeficiency and grant BMBF 01GM1111B to the PID-Net
Initiative) and was supported within the framework of the e:
Med research and funding concept CoNfirm (FKZ 01ZX1708F to
M. Boerries). S. Völkl and A. Mackensen were supported by the
German Research Foundation (VO 1835/3-1 and MA1351/12-1).
M.E. Maccari and F.G. Kapp were supported by an EXCEL-
Fellowship of the Faculty of Medicine, University of Freiburg,
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Figure S1. ALPS DNTs show a unique transcriptional profile. (A) Principal component (PC) analysis of RNA sequencing data on DNTs, CD8+ N+EDs, and
CD8+ LDs of three ALPS-FAS patients (P1–P3) and CD8+ LDs of three adult HDs (HD1–HD3). (B) Heatmap depicting up-regulated transcription factors among
DNT private DEGs (all significantly up-regulated in both comparisons of DNTs versus CD8+ N+EDs and DNTs versus CD8+ LDs). Log2 fold changes (log2 FCs) are
shown for the comparisons of DNTs versus CD8+ N+EDs and DNTs versus CD8+ LDs to compare the degree of dysregulation. (C) Heatmap of down-regulated
transcription factors among DNT private DEGs (all significantly down-regulated in both comparisons of DNTs versus CD8+ N+EDs and DNTs versus CD8+ LDs).
Relative expression (Z-score) of genes is shown and is color coded according to the legend. Rows are scaled to have a mean value of 0 and an SD of 1.
(D) Heatmaps showing expression levels (color code = log2 FC) of the top 30 up- or down-regulated genes identified in ALPS DNTs versus CD8+ N+EDs and
CD8+ LDs by RNA sequencing analysis (RNAseq) or selected up- or down-regulated molecules on ALPS DNTs by CyTOF/FACS in human naive T reg cells
(T reg_naive = CD3+CD4+CD25hiCD127lowCD45RA+) and memory T reg cells (T reg_mem = CD3+CD4+CD25hiCD127lowCD45RA−) compared with naive CD4+
T cells (Tn = CD3+CD4+CD45RA+CCR7+). Tn, T naive.
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Figure S2. ALPS patients and HDs have twomain DNT clusters. (A) UMAP projection of indicated T cell populations in seven ALPS-FAS patients and seven
HDs. (B) Heatmap comparing transcript levels of genes known to be dysregulated in ALPS DNTs in sorted ALPS FC DNT, HD FC DNT, HD cDNT, and HD N+ED
CD8+ T cells. Cells were sorted from ALPS patients P3, P6, and P22 and from HD4, HD5, and HD6. For one HD FC DNT sample, RNA was pooled from four HDs
to achieve sufficient RNA (HD5*). * indicates that a gene was significantly (adjusted P < 0.05) dysregulated compared with the reference HD CD8+ N+ED
population. (C) Heatmap of selected genes coding for lectins or enzymes involved in glycosylation. (D) Heatmap of selected genes involved in T cell activation
or differentiation. (E) Heatmap of up-regulated transcription factors found among ALPS DNT private DEGs in the first RNA sequencing analysis. For all
heatmaps, the relative expression (Z-score) of genes is shown and is color coded according to the legend. Rows are scaled to have a mean value of 0 and an SD
of 1. (F) Top 100 up- and down-regulated genes based on log2 fold changes in ALPS FC DNTs versus HD CD8+ N+EDs. Color code indicates log2 fold changes for
the indicated comparisons (1, 2, or 3).
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Figure S3. Small populations of CD4+ and CD8+ T cells share the FC T cell signature. (A) Number of significantly dysregulated genes (DEGs; adjusted P <
0.05) between the indicated comparisons by RNA sequencing analysis. Patient DNTs, CD8+ N+EDs, CD8+ LDs, and DNT-like CD8+ (CD8+CD28+CD57+) as well
as HD CD8+ LDs were included. (B) Example FACS plots showing percentages and phenotypes of FC CD4+ and CD8+ T cells in one ALPS patient and one HD.
Comparable results were generated in 9 ALPS patients and 20 HDs (data not shown). (C) Percentages of CD38+CD45RA+ cells of CD4+ T cells and of CD8+
T cells in peripheral blood (black symbols) and spleen (red symbol) of 13 ALPS patients. Lines indicate medians. (D) Representative histograms showing galectin
3 and pMYB expression in conventional and CD38+CD45RA+ T cells of one ALPS-FAS patient. Comparable results were generated in three ALPS patients.
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Figure S4. Frequencies of FC DNTs in peripheral blood of HDs. (A) Percentages of CD38+CD45RA+ cells among TCRαβ+ DNTs in peripheral blood of HDs
are shown related to age in years. (B) Absolute values of CD4+, CD8+, cDNTs, and CD38+CD45RA+ DNTs in peripheral blood of HDs related to age. Solid lines
represent linear regression analyses. R2 and P values are shown. (C) Absolute values of CD38+CD45RA DNTs/µl in peripheral blood of HDs (n = 43) versus
patients with acute EBV infection (n = 5) related to age.
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Figure S5. FC DNTs are regulated by FAS but also by mTOR, STAT3, and CTLA4. (A) Example plots showing proportions of active caspase 3–positive cells
among FC DNTs and cDNTs after ex vivo treatment with recombinant Fc-FASL. Comparative results were seen in cells from four different HDs. (B) Rep-
resentative plots of pS6 levels in FC CD4+ and FC CD8+ (CD38+CD45RA+; red) versus conventional CD4+ and CD8+ T cells (blue) of one ALPS-FAS patient with
or without anti-CD3/CD28 stimulation. Comparable results were achieved using cells of three additional ALPS patients. (C) Example FACS plots showing
percentages and phenotypes of CD38+CD45RA+ FC DNTs in patients with STAT3-activating mutation (STAT3 GOF), CTLA4 deficiency (CTLA4 Def.), and STAT3
loss of function mutation (STAT3 LOF). Additional patients (three with STAT3 GOF, three with CTLA-4 Def., and two with STAT3 LOF) were analyzed, with
similar results found (data not shown). Numbers indicate percentages. (D) Representative plots of pSTAT3 levels in FC CD4+ and FC CD8+ of one ALPS-FAS
patient with or without IL-21 stimulation. Analyses were performed in seven ALPS patients with similar results. (E) Summary plots showing the percentage of
viable FC DNTs (CD38+CD45RA+) of total TCRαβ+ DNTs ex vivo and after 24-h incubation with or without the indicated cytokines. Levels of significance by
mixed-effects analysis and Tukey’s multiple comparisons test. ns, not significant; *, P < 0.05.
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Six tables are available online inWord files. Table S1 depicts clinical, immunological, and genetic features of included patients. Table
S2 reports the sources of SLO and bone marrow samples. Table S3 lists flow cytometry antibodies. Table S4 lists the CyTOF
antibodies. Table S5 provides CyTOF analysis information for t-SNE. Table S6 lists CyTOF analysis information for
UMAP visualizations.
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